Homocysteine is related to neopterin and endothelin-1 in plasma of subjects with disturbed glucose metabolism and reference subjects

Angiology

Volumn 51, Issue 6, 2000, Pages 489-497

  Gottsater A ^a   Anwaar, I ^a   Eriksson, K F ^a   Mattiasson, I ^a   Lindgarde F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; GLYCOSYLATED HEMOGLOBIN; HOMOCYSTEINE; NEOPTERIN;

ADULT; AGE; AGED; AMINO ACID ANALYSIS; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE REGRESSION; PROTEIN DETERMINATION; REFERENCE VALUE;

EID: 0342733456     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100606     Document Type: Article

References (49)

1. Boushey C, Beresford S, Omenn G, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes, JAMA 274:1049-1057, 1995.
2. Mayer E, Jacobsen D, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27:517-527, 1996.
3. Welch G, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050, 1998.
4. Heijer MD, Koster T, Blom H, et al: Hyperhomocysteinernia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996.
5. Woo K, Chook P, Lolin Y, et al: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542-2544, 1997.
6. Bellamy M, McDowell I, Ramsey M, et al: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98:1848-1852, 1998.
7. Chambers J, McGregor A, Jean-Marie J, et al: Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy. Circulation 99:1156-1160, 1999.
8. Outinen P, Sood S, Liaw P, et al: Characterization of the stress-inducing effects of homocysteine. Biochem J 332:213-221, 1998.
9. Radomski M, Palmer R, Moncada S: The role of nitric oxide and cyclic GMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148:1482-1489, 1987.
10. Radomski M, Palmer R, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet II:1057-1058, 1987.
11. Ware J, Heistad D: Platelet-endothelium interactions. N Engl J Med 328:628-635, 1993.
12. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993.
13. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988.
14. Battistini B, D'Orléans-Juste P, Sirois P: Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab Invest 68:600-628, 1993.
15. Brude I, Finstad H, Sejleflot I, et al: Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 29:100-108, 1999.
16. Dudman N, Temple S, Guo X, et al: Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res 84:409-416, 1999.
17. Kojima S, Icho T, Kajiwara Y, et al: Neopterin as an endogenous antioxidant. FEBS Lett 304:163-166, 1992.
18. Fuchs D, Hausen A, Reibnegger G, et al: Neopterin as a marker for cell-mediated immunity. Immunol Today 9:150-155, 1988.
19. Huber C, Batchelor J, Fuchs D, et al: Immuneresponse associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 160:310-316, 1984.
20. Tatzber F, Rabl H, Koriska K, et al: Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 89:203-208, 1991.
21. Wiedermann C, Beimpold H, Herold M, et al: Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 22:1897-1901, 1993.
22. Gross S, Levi R: Tetrahydrobiopterin synthesis. An absolute requirement for cytokineinduced nitric oxide generation by vascular smooth muscle. J Biol Chem 267:25722-25729, 1992.
23. Sakai N, Kaufman S, Milstein S: Tetrahydrobiopterin is required for cytokine-induced nitric oxide production in a murine macrophage cell line. Mol Pharmacol 43:6-10, 1993.
24. Werner F, Werner E, Fuchs D, et al: Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 172:1599-1607, 1990.
25. 2+ calmodulin-dependent nitric oxide synthase from porcine cerebellum: Cofactor-role of tetrahydrobiopterin. FEBS Lett 277:215-219, 1990.
26. Hoogeveen E, Kostense PJ, Jager A, et al: Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study. Kidney Int 54:203-209, 1998.
27. Chico A, Perez A, Cordoba A, et al: Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41:684-693, 1998.
28. Munshi M, Stone A, Fink L, et al: Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovasular disease. Metabolism 45:133-135, 1996.
29. Hoogeveen E, Kostense P, Beks P, et al: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol 18:133-138, 1998.
30. Hultberg B, Agardh C, Agardh E, et al: Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 57:595-600, 1997.
31. Hofmann M, Kohl B, Sumbach M, et al: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21:841-848, 1998.
32. Cronin C, McPartlin J, Barry D, et al: Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 21:1843-1847, 1998.
33. Berglund G, Eriksson KF, Israelsson B, et al: Cardiovascular risk groups and mortality in an urban Swedish male population: The Malmö Preventive Project. J Int Med 239:489-497, 1996.
34. World Health Organisation: Expert committee on diabetes mellitus. Third report. WHO technical report series, no. 727. Geneva: WHO, 1985, pp 9-13.
35. Eriksson KF, Lindgärde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34:891-898, 1991.
36. Alc by a new lipidchromatographic assay: Methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32:1867-1872, 1986.
37. Burstein M, Scholnik H, Morfin R: Rapid method for the isolation of proteins from human serum by precipitation with polyanions. J Lipid Res 11:583-595, 1970.
38. Ubbink J, Vermaak W, Bissbort S: Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565:441-446, 1991.
39. Fiskerstrand T, Refsum H, Kvalheim G, et al: Homocysteine and other thiols in plasma and urine: Automated determination and sample stability. Clin Chem 39:263-271, 1993.
40. Norlund L, Grubb A, Fex G, et al: The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 36:175-178, 1998.
41. Anwaar I, Gottsäter A, Ohlsson K, et al: Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 8:310-317, 1998.
42. Upchurch GJ, Welch G, Fabian A, et al: Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 132:177-185, 1997.
43. Fonseca V, Mudaliar S, Schmidt B, et al: Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 47:686-689, 1998.
44. Fiorina P, Lanfredini M, Montanari A, et al: Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens 11:1100-1107, 1998.
45. Wollesen F, Brattstrom L, Refsum H, et al: Plasma total homocysteine, and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55:1028-1035, 1999.
46. Hoogeveen E, Kostense P, Jakobs C, et al: Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 242:389-394, 1997.
47. Malinow M, Duell P, Hess D, et al: Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 338:1009-1015, 1998.
48. Homocysteine Lowering Trialists Collaboration: Lowering blood homocysteine with folic acid-based supplements. Br Med J 316:894-898,1998.
49. Verhaar M, Wever R, Kastelein J, et al: 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97:237-241, 1998.